Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

One main concern is to what extent insurance providers will cover such a drug, given the abundance of cheaper alternatives. The FDA has already approved more than a dozen antipsychotics for ...

The prescription drug has been all over the news in the past couple of years - but the name Ozempic has become something of a ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...

WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...